source
- Axoltis reports Phase 2 failure of experimental ALS drug but notes small signalAxoltis Pharma, a French biotech, announced that its Phase 2 trial of an experimental ALS therapy did not meet its primary endpoints. The company said the data were noisy but observed a modest tre…
- J&J and Contineum's oral M1 inhibitor fails second mid-stage depression trialContineum Therapeutics and Johnson & Johnson reported that their oral M1 receptor inhibitor, known as PIPE-307 or JNJ-5120, did not meet its primary endpoints in a Phase II study for major depressi…